Beam Therapeutics

Company snapshot

Beam Therapeutics Inc. is an American [biotechnology](en.wikipedia.org/wiki/Biotechnology) company conducting research in the field of [gene therapies](en.wikipedia.org/wiki/Gene_therapy) and [genome editing](en.wikipedia.org/wiki/Genome_editing). The company is headquartered in [Cambridge, Massachusetts](en.wikipedia.org/wiki/Cambridge,_Massach). In the development of therapies, the company relie

• 3 approved product(s) across US/EU regulatory metadata.
• 10 active pipeline program(s) linked via ClinicalTrials.gov.
• 14 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Beam Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Beam Therapeutics.

1. Jun 8, 2026 Clinical update

   Beam Organics Dream Powder — Unknown

2. Jun 8, 2026 Clinical update

   BEAM Dream Powder — Unknown

3. Jun 8, 2026 Clinical update

   BEAM-301: Single dose of BEAM-301 administered by IV — Phase 2

4. Jun 8, 2026 Clinical update

   Allogeneic anti-CD7 CAR-T cells (BEAM-201) — Phase 1

5. Jun 8, 2026 Clinical update

   PRDR — Unknown

View all clinical trial activity →

• What is Beam Therapeutics?

  Beam Therapeutics is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker BEAM. Primary therapeutic focus areas include Sleep, T-Cell Acute Lymphoblastic Leukemia/Lymphoma, Sickle Cell Disease, Lymphoblastic Lymphoma, Glycogen Storage Disease Typ

• Is Beam Therapeutics publicly traded?

  Yes. Beam Therapeutics is listed with ticker BEAM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Beam Therapeutics develop or market?

  We link 14 drug profile(s) where Beam Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/beam-therapeutics#company-drugs.

• What are the latest developments for Beam Therapeutics?

  In the last 12 months our linked public records show 10 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Beam Therapeutics focus on?

  Beam Therapeutics focuses on Sleep, T-Cell Acute Lymphoblastic Leukemia/Lymphoma, Sickle Cell Disease based on our analysis of their pipeline programs and drug development activities.